Thus, these data suggest that miR-21 and its IL-2/IL-15/STAT5 regulators play a key role in the pathogenesis of CTCL and that miR-21 may serve as a potential therapeutic target in CTCL. The gene discussed is IL15; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.